• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Agios Pharmaceuticals

edit

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism. It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company’s therapeutics are also used in the areas of autoimmune, inflammatory, and neurological diseases. Agios Pharmaceuticals, Inc. was formerly known as CANCER METABOLISM THERAPEUTICS, INC. and changed its name to Agios Pharmaceuticals, Inc. in April 2008. The company is based in Cambridge, Massachusetts.

Recent Milestones

edit

• 
  Agios Pharmaceuticals received $78M in Series C funding. (11/17/11)
  Posted 11/17/11 at 6:52pm via finsmes.com
• 
  Agios Pharmaceuticals — Agios adds Scott Biller as Chief Scientific Officer (9/21/10)
  Posted 9/21/10 at 10:28am via masshightech.com
• 
  Agios Pharmaceuticals — Agios scores $130M upfront from Celgene pact (4/15/10)
  Posted 4/15/10 at 7:31pm via fiercebiotech.com
• 
  Agios Pharmaceuticals received () in Venture Round funding. (12/23/09)
  Posted 12/29/09 at 9:24pm via finsmes.com
• 
  Agios Pharmaceuticals added David Schenkein as CEO.
  Posted 12/29/09 at 9:24pm
• 
  Agios Pharmaceuticals added Lewis C. Cantley as Co-Founder.
  Posted 12/29/09 at 9:24pm
• 
  Agios Pharmaceuticals added Kevin Starr as Interim CEO.
  Posted 4/28/13 at 1:53am
• 
  Agios Pharmaceuticals added Kevin Starr as Board Member.
  Posted 4/28/13 at 1:54am

Videos

Screenshots

edit

Above: Home Page
Uploaded: 12/30/09

Sources

1. Agios Pharmaceuticals Receives Funding to Support Research into Novel Therapeutics and Diagnostics for Brain Cancer (finsmes.com) [edit]
2. Agios Pharmaceuticals Raises $78M in Series C Financing (finsmes.com) [edit]
Agios scores $130M upfront from ambitious Celgene pact (fiercebiotech.com) [edit]
Mass High Tech (masshightech.com) [edit]